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Around 15% of colorectal cancers (CRCs) show microsatellite instability (MSI) due to dysfunction of the mismatch repair system
(MMR). As a consequence of this, MSI tumours tend to accumulate errors in mononucleotide repeats as those in genes implicated in
repairing double-strand breaks (DSBs). Previous studies have shown that irinotecan (CPT-11), a chemotherapy agent inducing DSB, is
more active in MSI than in microsatellite stable (MSS) CRC. The purpose of this study was to compare the sensitivity to CPT-11 in a
series of CRC cell lines with either proficient or deficient MMR and to assess the mutational status of two DSB repair genes, MRE11
and RAD50, in these cell lines. hMLH1-deficient cell lines due to either epigenetic silencing or mutation showed very similar IC50 and
were four- to nine-fold more sensitive to CPT-11 than the MSS line. Cell lines harbouring mutations in both MRE11 and RAD50 were
most sensitive to CPT-11. We conclude that MSI cell lines display higher sensitivity to CPT-11 than MSS cells. Mutation of MRE11 and
RAD50 could account for this difference in response to CPT-11. Future clinical trials tailoring chemotherapy regimens based on
microsatellite status are warranted.
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DNA mismatch repair (MMR) proteins correct three types of
defects that escape the intrinsic proofreading exonuclease activity
of DNA polymerases: (i) single base-pairing errors, (ii) unequal
crossing over between microsatellites, and (iii) insertion/deletion
loops that result from slippage during replication of repetitive
sequences or during recombination. Microsatellites are multiple
tandem repeats of a small number of nucleotides that are very
prone to these errors; therefore MMR system activity is critical for
their maintenance (Kunkel, 2004; Jiricny, 2006). On account of the
fact that microsatellites are widely distributed in our genome,
mutations of MMR genes affect multiple genetic targets, as those
described in mononucleotide repeats of the DNA double-strand
breaks (DSBs) repair genes BLM, ATR, DNA-PK, BRCA2, RAD50,
and MRE11.
Colorectal cancers (CRCs) are classified as either displaying
high-frequency microsatellite instability (MSI-H), low-frequency
MSI (MSI-L), or microsatellite stability (MSS) depending on the
number of microsatellite loci showing errors by previously defined
consensus criteria (Giardiello et al, 2001). Around 15–20% of
CRCs are MSI-H, mainly due to epigenetic silencing of the hMLH1
gene promoter (Herman et al, 1998), whereas 2–3% of the total of
CRCs are due to germ-line mutations in the MMR genes hMLH1,
hMSH2, hMSH6, and PMS2, which are the cause of hereditary non-
polyposis CRC (HNPCC) cases (Aaltonen et al, 1998; Salovaara
et al, 2000). MSI-H sporadic tumours are characterised by high
histologic tumour grade, right-sided location, young age of onset,
lower pathological stage, mucinous phenotype with prominent
tumour infiltrating lymphocytes, and better prognosis in terms of
overall survival than MSI-L/MSS cases (Gryfe et al, 2000; Popat
et al, 2005).
CPT-11 is a camptothecin analogue that binds reversibly to DNA
topoisomerase I (TOP1) and traps it on the DNA strand, so
cleavable complexes will remain stabilised and DNA DSBs will be
generated after DNA or RNA polymerases collide with those
complexes. This mechanism of action has been named as ‘the fork
collision model’ (Pommier, 2006). MMR-deficient CRC tumours
and cell lines frequently tend to accumulate mutations within
microsatellite repeats of genes implicated in DSB repair pathway
(eg, MRE11 and RAD50) (Giannini et al, 2002; Koh et al, 2005),
suggesting an enhanced sensitivity of these tumours to camp-
tothecin analogues. In accordance with this fact, emerging clinical
data suggest that MSI-H CRC patients may obtain more benefit
from CPT-11-based chemotherapy than patients bearing MSS
tumours (Fallik et al, 2003; Bertagnolli et al, 2006). Still, preclinical
evidence suggesting a higher sensitivity of MMR-deficient tumours
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sto irinotecan (CPT-11) is controversial due to discrepant results
coming from different studies (Hausner et al, 1999; Jacob et al,
2001; Magrini et al, 2002; Fedier and Fink, 2004).
The objective of this study was to compare the sensitivity to
CPT-11 in a series of CRC cell lines classified based on the
microsatellite and the mutational status in coding mononucleotide
repeats of MRE11 and RAD50. Additionally, we aimed to assess the
differences in sensitivity between cell lines with a genetic mutation
in MMR genes (MLH1 or MSH6), which resemble HNPCC, and cell
lines with silencing of the hMLH1 gene due to the promoter
hypermethylation, such as sporadic MSI-H CRC cases.
MATERIALS AND METHODS
Cell lines and culture conditions
HCT-116, SW-48, RKO, and HCT-15 were kindly provided by Dr
Manel Esteller (Cancer Epigenetics Laboratory, Spanish National
Cancer Centre, Madrid, Spain). HT-29 was obtained from the
American Type Culture Collection (Manassas, VA, USA). The
microsatellite status of cell lines, the MMR gene mutational status
and the analysis of the methylation of hMLH1 promoter was
ascertained from the literature and are summarised in Table 1
(Suter et al, 2003). Cells were maintained as monolayers at 371Ci n
5% CO2 air in DMEM:Ham’s F-12 containing 10% foetal
bovine serum, glutamine (2mM), and penicillin/streptomycin
(50IUml
 1).
Western blotting
Cells were grown in 100-mm dishes until subconfluence. After
removal of media, cells were washed twice with ice-cold PBS and
scraped into ice-cold lysis buffer. After removal of cell debris by
centrifugation, protein concentration was determined by Lowry
assay (DC Protein assay, Bio-Rad, Hercules, CA, USA). Lysate
samples containing equal amounts of protein were then added to
SDS–PAGE loading buffer with 5% b-mercaptoethanol and heated
5min at 1001C. Electrophoretic transfer to nitrocellulose mem-
branes was followed by immunoblotting with the primary
antibodies. Finally, membranes were hybridised with the appro-
priate horseradish peroxidase-conjugated secondary antibody
(Amersham Pharmacia Biotech, Little Chalfont, UK), and were
detected through chemiluminescence with the SuperSignal West
Dura Extended Duration Substrate (Pierce, Rockford, IL, USA).
Rabbit polyclonal antibodies against Mlh-1, Msh-2, and Msh-6
(Upstate, Dundee, UK) were used at 1:1000.
Detection of mononucleotide repeats mutations of MRE11
and RAD50
Mutation analyses for poly(T)11 nucleotide repeats in IVS-4 of
MRE11 and poly(A)9 nucleotide repeats in the ORF of RAD50 were
performed on genomic DNA extracted using the DNeasy kit
(Qiagen, Valencia, CA, USA). PCR conditions and primers were set
up as described previously (Kim et al, 2001; Giannini et al, 2002).
A3 - ml aliquot of the product was sequenced using the forward and
reverse primers with an ABI BigDye TerV3.1 Cycle Sequencing kit
on an ABI 9700 thermocycler (Applied Biosystems Inc., Foster
City, CA, USA). The data were analysed using Sequencher 4.6
software (Gene Codes Corporation, Ann Arbor, MI, USA).
Cytotoxicity assays and treatment of cultured cells
CPT-11 was obtained from Mayne Pharma Plc (Warwickshire,
UK), and it was diluted in DMEM immediately before use. Drug
cytotoxicity assays were performed using a modified tetrazolium
dye colorimetric assay (cell proliferation reagent WST-1, Roche
Applied Science, Penzberg, Germany). Viable cells will metabolise
WST-1 to formazan by mitochondrial dehydrogenases and the
quantification of formazan dye directly correlates with the number
of metabolically active cells that was determined by a scanning
microplate reader (ELISA reader). Three thousand cells were
seeded per well in 96-well plates and were treated with increasing
concentrations of CPT-11 for 48h (1–100nmoll
 1) after 24h.
After that, cells were washed and incubated in drug-free medium
for another 3 days. On day 6, WST-1 was added to each well and
further incubated at 371C for 1h. Absorbances were measured and
mean values of a minimum of six wells were calculated. Cultures in
the absence of drugs were used as positive controls. The
percentage of surviving cells at each concentration relative to the
non-treated group was plotted and the drug concentrations
resulting in 50% of growth inhibition (IC50) were calculated by
linear regression analysis of the obtained dose–response curves.
Cell cycle analysis
Cells were fixed with 70% ethanol at  201C overnight, followed by
treatment with 20mgml
 1 RNAse A and staining with propidium
iodide. Fluorescence was measured on a Beckman coulter Epics
s
XL flow cytometer.
Statistical analyses
Differences in CPT-11 sensitivity between cell lines displaying MSI
or MSI-L/MSS were analysed using a two-sided t-test with Po0.05
considered statistically significant. Statistical analyses and linear
regression for dose–response curves were performed using
GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA).
RESULTS
Expression of MMR proteins and mutational status of
MRE11 and RAD50
Cell lines were selected to perform the experiments based on their
microsatellite status. As shown in Table 1, four cell lines showed
MSI. HCT-116 and HCT-15 presented biallelic mutations in
hMLH1, hMSH6 genes, respectively, resembling cases of patients
Table 1 MS, hMLH1 promoter methylation, MMR genes status, and mutations in mononucleotide repeats of MRE11 and RAD50 alleles in cell lines
Cell line MS status
hMLH1 promoter
methylation hMLH1 hMSH2 hMSH6
RAD50 poly(A)9
exon 13
MRE11 poly(T)11
intron 4
HCT-116 MSI-H   mut wt wt  1/wt  2/ 1
HCT-15 MSI-L   wt wt mut wt/wt  2/wt
SW-48 MSI-H + wt wt wt wt/wt  1/ 1
RKO MSI-H + wt wt wt  1/wt  2/ 1
HT-29 MSS   wt wt wt wt/wt wt/wt
MS¼microsatellite; MSI-H¼high-frequency microsatellite instability; MSI-L¼low-frequency microsatellite instability; MSS¼microsatellite stability; mut¼mutant; wt¼wild type;
 ¼negative; +¼positive.
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saffected by HNPCC. SW-48 and RKO had the hMLH1 gene
promoter silenced transcriptionally by hypermethylation as those
sporadic tumours showing MSI-H. Contrary, HT-29 displayed
normal MMR gene functioning as the majority of sporadic CRC
cases. Expression of hMLH1, hMSH2, and hMSH6 were ascertained
by western blot (Figure 1). All CRC cell lines used in our study
expressed some level of Msh2. The expression of Mlh1 was
undetectable in HCT-116, SW-48, and RKO, whereas Msh6 protein
was detected in all cell lines except for HCT-15, corresponding to
the known mutational status.
We have studied the presence of mutations in microsatellite
regions of MRE11 and RAD50 that are involved in surveillance
and correction of DSBs, as those generated after treatment with
CPT-11. In particular, we have investigated the occurrence of
a frameshift mutation in a coding poly(A) repeat of RAD50 and
a shortening in an intronic poly(T) repeat of MRE11. These
mutations result in a truncated protein in the case of RAD50 and
an aberrant transcript due to skipping of exon 5 and a premature
stop codon introduction in MRE11. We showed that all MSI cell
lines harboured mutations in the poly(T) tract of MRE11 (Table 1).
In addition, HCT-116 and RKO presented mutations in the poly(A)
of RAD50. The MMR-proficient cell line HT-29 was wild type for
both genes.
Cytotoxicity of CPT-11 to CRC cell lines classified by
microsatellite status
Dose–response curves were plotted to determine the IC50 and 95%
confidence intervals for each cell line (Figure 2). As shown in
Figure 3, hMLH1-deficient cell lines due to either epigenetic
silencing (RKO) or biallelic mutation (HCT-116) were the most
sensitive to CPT-11 in comparison to the MMR-proficient HT-29,
which had an IC50 four- to nine-fold higher (MSI-H vs MSI-L/MSS,
Po0.001). In addition, both cell lines presenting hypermethylation
of hMLH1 had a similar IC50 showing consistency in our results.
However, the hMSH6-deficient cell line, HCT-15, displayed
sensitivity to CPT-11 closer to the MSS cell line than the rest of
MSI cell lines, suggesting a minor role of hMSH6 deficiency in the
sensitivity to CPT-11.
Regarding the mutational status of DSB repair genes and
response to CPT-11, we have observed that HCT-116 and RKO,
which harboured mutations in both MRE11 and RAD50, were the
most sensitive cell lines. On the contrary, HT-29 was wild type for
both genes and was most resistant to CPT-11. Noteworthy, HCT-15
was heterozygous for the poly(T) mutation in MRE11 and wild
type for RAD50 and was less sensitive to CPT-11 than HCT-116
and RKO. Therefore, the presence of mutations in DSB repair
genes may explain the differences in sensitivity between MSI and
MSS cells, whereas the number of affected DSB repair genes may
account for different levels of sensitivity to CPT-11.
Cell cycle analysis after treatment with different
concentrations of CPT-11
We did perform cell cycle analysis based on DNA content after
exposure to two different concentrations of CPT-11 for 48h. We
selected 5 and 10mmoll
 1 because the former is around the IC25 in
the most sensitive cells (MMR deficient) and the latter is around
the IC50 in the least sensitive (MMR proficient). Moreover, these
concentrations are similar to peak plasma concentrations after
CPT-11 infusion in human subjects (Mathijssen et al, 2001). As
shown in Figure 4, the percentage of cells in S phase without
treatment was 14.7–39.6%, and in G2 phase was 14.7–27.1%.
Treatment with CPT-11 decreased the percentage of cells in
S phase and elicited an arrest in the G2/M phase of cell cycle. When
we compared the changes in the percentage of cells in S, G1 and
HT29
160 kDa
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-actin
HCT15 HCT116 RKO SW48
Figure 1 Expression of hMSH6 (160kDa), hMSH2 (100kDa), hMLH1
(83kDa), and b-actin (42kDa) were analysed by western blotting in whole-
cell protein extracts.
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Figure 2 Cytotoxicity of CPT-11 to human colorectal cancer cell lines.
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Figure 3 Cytotoxicity to CPT-11 of CRC cell lines. Histograms
represent the IC50 and error bars represent 95% CI. IC50, concentrations
resulting in 50% of growth inhibition; 95% CI, 95% confidence intervals.
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sG2/M between control and cells treated with 10mmoll
 1 of CPT-11,
RKO, and HCT-116 showed the most striking changes followed by
HT-29. SW-48 elicited the same changes in G1, G2/M, and S
phases; however, differences in relative percentages were smaller
than in the other three cell lines. Overall, a similar pattern of
changes in the cell cycle was observed in all cell lines.
DISCUSSION
The aim of this study was to correlate the cytotoxicity of the TOP1
inhibitor, CPT-11, with the mutational status of MMR and DSB
genes in CRC cell lines. Our experimental data show that three cell
lines displaying MSI-H due to an hMLH1 inactivation are four- to
nine-fold more sensitive to CPT-11 than an MSS cell line and that
this difference in sensitivity is apparently independent from the
original cause of the hMLH1 deficiency. Moreover, cell lines with
either hMLH1 promoter hypermethylation or biallelic mutation
have similar IC50 values. Additionally, we noticed that the hMSH6-
deficient cell line, HCT-15, has sensitivity to CPT-11 closer to the
MSS cell line than to the other MSI cell lines. In addition to this,
those cell lines doubly mutated in MRE11 and RAD50 were more
sensitive to CPT-11 than those cells heterozygous for the poly(T)
mutation in MRE11, or wild type for both genes. Cell cycle analyses
showed G2/M arrest and decrease in the number of cells in the S
phase. These results are in agreement with the ‘fork collision
model’ and the S-phase specificity of CPT-11. Therefore, this work
reinforces previous reports of higher sensitivity of MMR-deficient
cell lines to CPT-11 and offers a potential explanation for it (Jacob
et al, 2001; Magrini et al, 2002).
Several authors have demonstrated that MSI is a prognostic
marker in patients with CRC (Gryfe et al, 2000; Popat et al, 2005).
Additionally, the presence of MSI may have a predictive value of
response to 5-FU and CPT-11 in CRC. One multicentre retro-
spective review of clinicopathological data (Benatti et al, 2005) as
well as two retrospective analysis of clinical trials in the adjuvant
setting (Watanabe et al, 2001; Ribic et al, 2003) have suggested that
patients with MSI-H may have less sensitivity to 5-FU-based
chemotherapy than those with MSI-L/MSS tumours. In accordance
with this fact, insensitivity to 5-FU has been consistently proved in
various preclinical models with MSI-H CRC cell lines (Carethers
et al, 1999; Meyers et al, 2001, 2005).
However, sensitivity of CPT-11 in this subset of tumours is not
so clearly defined at both the preclinical and the clinical levels.
Two independent research groups have reported resistance to
camptothecins in MMR-deficient cell lines (Hausner et al, 1999;
Fedier et al, 2001). In contrast with these reports, we and others
(Jacob et al, 2001; Magrini et al, 2002) have demonstrated higher
sensitivity to CPT-11 in MMR-deficient human CRC cell lines than
in MMR-proficient cells and G2/M arrest after exposure to CPT-11.
Likewise, the body of evidence supporting the sensitivity to
CPT-11 in MSI-H CRC at the clinical level is limited. A
retrospective analysis of 73 metastatic CRC patients who received
second-line CPT-11-based chemotherapy showed a higher
response rate in the group of tumours displaying MSI-H compared
with the MSI-L/MSS group (57.1 vs 10.8%, P-value¼0.009) (Fallik
et al, 2003). Bertagnolli et al (2006) analysed the differences in
disease-free survival in 482 patients enroled in the CALGB 89803
adjuvant study according to the microsatellite status . A total of
1264 patients with resected stage III colon cancer were randomized
to receive adjuvant 5-FU-based treatment with or without CPT-11.
Sixteen percent of patients had MSI-H tumours. Regarding the
population receiving CPT-11 in addition to 5-FU, those patients
bearing MSI-H tumours presented a higher disease-free survival
than those patients with MSI-L/MSS tumours. Despite this,
improvement in survival did not achieve statistical significance,
although there was a clear trend for a prolongation in disease-free
survival (long rank¼0.18). Several reasons may explain the lack of
significant differences found in this study. First, the results may
not be mature enough due to the limited follow-up of the patients
(mean follow-up¼3.8 years). Second, the retrospective nature of
this analysis along with the restriction to only one-third of the
patients included in the clinical study may either be generating an
uncontrolled bias or limiting the power to detect differences.
Finally, adjuvant CPT-11-based chemotherapy has globally failed
to demonstrate a significant improvement in terms of progression-
free survival in stage III CRC in three different studies (van Cutsem
et al, 2005; Ychou et al, 2005; Saltz et al, 2007), which suggests that
factors other than MSI status play an important role as prognostic
factors in the adjuvant setting.
The current evidence in the treatment of advanced CRC patients
shows that multiagent chemotherapy incorporating either oxali-
platin (de Gramont et al, 2000; Giacchetti et al, 2000) or CPT-11
(Douillard et al, 2000; Saltz et al, 2000) onto a backbone of
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Figure 4 Exposure to CPT-11 for 48h results in G2/M arrest. CRC cell lines were treated with 5mM, 10mM CPT-11, and supplemented medium (control).
Cell cycle analyses were performed by FACS.
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sfluoropyrimidines is superior to traditional regimens of fluoro-
pyrimidines alone (Kelly and Goldberg, 2005). However, the
available randomised studies have failed to demonstrate that
a first-line oxaliplatin combined with infusional 5-FU schedule,
or a CPT-11 with infusional 5-FU schedule, was better than the
other for the global population of patients with advanced CRC
(Giacchetti et al, 2000; Tournigand et al, 2004). Further exploration
on the role of microsatellite status to select the most appropriate
drug combination for the first-line treatment of metastatic CRC
may be considered in the design of future clinical trials.
One of the questions that still remains partially unanswered is
the exact mechanism why MSI-H cells are more sensitive to
camptothecins than MSS cells. Several studies have demonstrated
that deficiency in the MMR genes leads to secondary mutations in
microsatellite tracts as those present in the monucleotide repeats
regions of the principal caretaker genes implicated in the repair of
DSB, such as the Mre11/Nbs1/Rad50 protein complex (Giannini
et al, 2004; Koh et al, 2005). These observations have been
extended to tumour series from sporadic and familial MSI-H CRC
cases (Miquel et al, 2007). We have suggested that cell lines
harbouring mutations in both MRE11 and RAD50 were the most
sensitive to CPT-11. Previous reports showed that mutations in
these genes are also associated with increased response to
g-irradiation, another type of DNA-damaging agent causing DSB
(Koh et al, 2005). In addition, the preferential cytotoxic effect
showed by another DNA-damaging agent, Bleomycin, in MSI-H
cell lines might be explained by the same genetic defect (Li et al,
2004). Still, further functional studies should be carried out to
elucidate the relevance of this complex in the chemosensitivity
to CPT-11 and other DNA-damaging agents.
In conclusion, our study reinforces previous preclinical results
suggesting an increased sensitivity to CPT-11 in MSI-H CRC cell
lines. This chemosensitivity is explained by an impairment of the
mechanism to repair DSB caused by DNA-damaging agents
secondary to the microsatelite instability. In addition, we have
demonstrated that no differences in sensitivity exist between cell
lines with inactivation of the Mlh-1 function secondary to biallelic
mutations and those with epigenetic silencing of the promoter.
These results together with the available clinical information
support the design of more clinical trials with CPT-11-based
chemotherapy regimens in the adjuvant and advanced settings
according to a tailored approach that combines clinical character-
istics and the MSI status as a predictive factor of response to
chemotherapy.
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